GLP1ProviderCompare
NexLife $215Yucca Health $258IVIM Health $278Mochi Health $278Found $289ShedRx $289OrderlyMeds $299SkinnyRx $299Amble Health $300Oak Longevity $133 semaYucca Health $146 semaOrderlyMeds $149 semaNexLife $165 semaall-in monthly · verified 2026-08-05 · databaseNexLife $215Yucca Health $258IVIM Health $278Mochi Health $278Found $289ShedRx $289OrderlyMeds $299SkinnyRx $299Amble Health $300Oak Longevity $133 semaYucca Health $146 semaOrderlyMeds $149 semaNexLife $165 semaall-in monthly · verified 2026-08-05 · database

Guides & science · 3 min read

503A vs. 503B Pharmacies: The Distinction That Decides Compounded Drug Quality

Patient-specific pharmacies versus FDA-registered outsourcing facilities — who inspects them, which standards apply, why the difference grew teeth after the shortage ended, and the five questions that verify any program's pharmacy.

Quick answer

Patient-specific pharmacies versus FDA-registered outsourcing facilities — who inspects them, which standards apply, why the difference grew teeth after the shortage ended, and the five questions that verify any program's pharmacy.

Every compounded GLP-1 comes from one of two legal species of pharmacy, and the difference — Section 503A versus Section 503B of the FDCA — is the single most useful piece of jargon a compounded-drug buyer can own. It determines who inspects the facility, which quality standards apply, and how the post-shortage rules bite.

503A: the traditional compounding pharmacy

A 503A pharmacy fills patient-specific prescriptions — one script, one preparation — under primarily state board of pharmacy oversight, meeting USP standards (like USP <797> for sterile compounding) rather than full federal manufacturing rules. This is the neighborhood-compounder model scaled up by telehealth, and it is the legal theory most 2026 GLP-1 programs operate under: patient-specific prescriptions, often citing individualized doses or formulations. Its structural weakness is variance — quality runs from excellent to alarming across thousands of state-regulated facilities, and FDA inspection is the exception, not the routine.

503B: the outsourcing facility

A 503B outsourcing facility registers with the FDA, can produce large batches without patient-specific prescriptions, and must meet full Current Good Manufacturing Practice (cGMP) — the same framework governing pharmaceutical manufacturers — under routine FDA inspection. During the shortage, 503Bs supplied much of the telehealth market at scale. Post-shortage, they were the first door closed: large-scale copying was required to stop by March 19, 2025, and the FDA's April 2026 proposed rule would exclude tirzepatide, semaglutide, and liraglutide from the 503B bulks list outright — which is why the surviving compounded market is overwhelmingly 503A patient-specific territory, with all the variance that implies.

What this means for your five questions

The pharmacy behind a program is knowable, and asking is the diligence. Five questions do the work: Which pharmacy, by name, fills the prescription? (In our database, NexLife names six partners, Mochi owns its facility, Noom names Tailor Made — most programs name none, and silence is data.) Is it 503A or 503B? Which state boards license it, and is it licensed to ship to yours? Is it PCAB-accredited (the compounding-specific accreditation that signals audited standards)? Will they share a certificate of analysis for the batch — identity, potency, sterility, endotoxin? A program that answers all five plainly has told you more about its product than any price can; every provider page on this site records what each program discloses, and the pharmacy-disclosure field in the database exists precisely because the answer is usually "not named."

Frequently asked

What is the difference between a 503A and 503B pharmacy?

503A pharmacies compound patient-specific prescriptions under state oversight and USP standards; 503B outsourcing facilities produce batches under full FDA cGMP with routine federal inspection. Different law, different quality floor.

Which type makes compounded GLP-1s now?

After the March 2025 cutoff and the April 2026 proposed bulks-list exclusion, large-scale 503B GLP-1 compounding has largely wound down; the surviving market operates through 503A patient-specific prescriptions — the contested pathway described in our legal-status guide.

How do I verify a compounding pharmacy?

Get its name from the program, confirm state licensure with the state board of pharmacy, check PCAB accreditation, and ask for a certificate of analysis covering identity, potency, and sterility for your batch. Refusal to name the pharmacy is itself an answer.